Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
复制标题
DOI：
10.1136/rmdopen-2022-002876
复制
发表时间：
2023-03
期刊：
影响因子：
6.2
通讯作者：
Vital, Ed
中科院分区：
文献类型：
--
作者：
Burska, Agata;Rodriguez-Carrio, Javier;Biesen, Robert;Dik, Willem A.;Eloranta, Maija-Leena;Cavalli, Giulio;Visser, Marianne;Boumpas, Dimitrios T.;Bertsias, George;Wahren-Herlenius, Marie;Rehwinkel, Jan;Fremond, Marie-Louise;Crow, Mary K.;Ronnblom, Lars;Conaghan, P. G.;Versnel, Marjan;Vital, Ed
系统回顾旨在评价I型干扰素（IFN-I）通路激活的测定方法的文献，并协调相关术语。在三个数据库中检索IFN-I和风湿性肌肉骨骼疾病的报告。提取并总结了关于测量IFN-I的测定的性能指标和真实性测量的信息。一个欧洲土地使用权联盟工作队小组评估了可行性，并制定了共识术语。在10037篇摘要中，276篇符合数据提取的合格标准。一些人报告了一种以上的技术来测量IFN-I途径激活。因此，276篇论文产生了412种方法的数据。使用以下方法测量IFN-I途径活化：qPCR（n=121）、免疫测定（n=101）、微阵列（n=69）、报告细胞测定（n=38）、DNA甲基化（n = 14）、流式细胞术（n = 14）、细胞病变效应测定（n=11）、RNA测序（n=9）、空斑减少测定（n=8）、Nanostring（n=5）、亚硫酸氢盐测序（n=3）。总结了各试验的原理，以确定含量有效性。列出了n=150/412次检测的并行有效性（与其他IFN检测的相关性）。可靠性数据是可变的，并提供了13个测定。基因表达和免疫测定被认为是最可行的。产生了定义IFN-I研究和实践的不同方面的共识术语。不同的方法已被报道为IFN-I测定，并且这些方法在它们测量IFN-I途径活化的哪些元素或方面以及如何测量方面有所不同。没有“金标准”代表整个IFN途径，有些可能对IFN-I没有特异性。可靠性或比较测定的数据有限，可行性是许多测定的挑战。协商一致的术语应提高报告的一致性。
To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology. Three databases were searched for reports of IFN-I and rheumatic musculoskeletal diseases. Information about the performance metrics of assays measuring IFN-I and measures of truth were extracted and summarised. A EULAR task force panel assessed feasibility and developed consensus terminology. Of 10 037 abstracts, 276 fulfilled eligibility criteria for data extraction. Some reported more than one technique to measure IFN-I pathway activation. Hence, 276 papers generated data on 412 methods. IFN-I pathway activation was measured using: qPCR (n=121), immunoassays (n=101), microarray (n=69), reporter cell assay (n=38), DNA methylation (n=14), flow cytometry (n=14), cytopathic effect assay (n=11), RNA sequencing (n=9), plaque reduction assay (n=8), Nanostring (n=5), bisulphite sequencing (n=3). Principles of each assay are summarised for content validity. Concurrent validity (correlation with other IFN assays) was presented for n=150/412 assays. Reliability data were variable and provided for 13 assays. Gene expression and immunoassays were considered most feasible. Consensus terminology to define different aspects of IFN-I research and practice was produced. Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how. No ‘gold standard’ represents the entirety of the IFN pathway, some may not be specific for IFN-I. Data on reliability or comparing assays were limited, and feasibility is a challenge for many assays. Consensus terminology should improve consistency of reporting.
登录
查看更多内容
干扰素诱导趋化因子转录水平升高与系统性红斑狼疮患者疾病活动和器官损伤的关联。
影响因子：
4.9
作者：
Fu, Qiong;Chen, Xiaoqing;Cui, Huijuan;Guo, Yanzhi;Chen, Jing;Shen, Nan;Bao, Chunde
通讯作者：
Bao, Chunde
影响因子：
--
作者：
Bauer, Jason W.;Petri, Michelle;Batliwalla, Franak M.;Koeuth, Thearith;Wilson, Joseph;Slattery, Catherine;Panoskaltsis-Mortari, Angela;Gregersen, Peter K.;Behrens, Timothy W.;Baechler, Emily C.
通讯作者：
Baechler, Emily C.
DOI：
10.1084/jem.20021553
发表时间：
2003-03-17
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Bennett L;Palucka AK;Arce E;Cantrell V;Borvak J;Banchereau J;Pascual V
通讯作者：
Pascual V
I型干扰素反应基因在已建立的类风湿关节炎中的表达与临床参数无关。
影响因子：
4.9
作者：
de Jong TD;Blits M;de Ridder S;Vosslamber S;Wolbink G;Nurmohamed MT;Verweij CL
通讯作者：
Verweij CL
影响因子：
4.9
作者：
Lee HM;Mima T;Sugino H;Aoki C;Adachi Y;Yoshio-Hoshino N;Matsubara K;Nishimoto N
通讯作者：
Nishimoto N